NCT01563068View on ClinicalTrials.gov

Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Psoriasis
Interventions
DRUG

Calcipotriene 0.005% Foam

Topical application applied twice a day for 15 days

Trial Locations (9)

19103

Investigational Site, Philadelphia

30060

Investigational Site, Marietta

32174

Investigational Site, Ormond Beach

33609

Investigational Site, Tampa

40217

Investigational Site, Louisville

46256

Investigational Site, Indianapolis

60611

Investigational Site, Chicago

77030

Investigational Site, Houston

92123

Investigational Site, San Diego

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Mayne Pharma International Pty Ltd

INDUSTRY

NCT01563068 - Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis | Biotech Hunter | Biotech Hunter